6533b820fe1ef96bd1279a22

RESEARCH PRODUCT

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma

Daniela CarboneGodefridus J. PetersUgo PerriconeElisa GiovannettiBtissame El HassouniGirolamo CirrincioneGiovanna Li PetriGiovanna Li PetriBarbara ParrinoStella CascioferroVincenzo ArizzaPatrizia DianaNiccola FunelAlessandro Padova

subject

antiproliferative activityPancreatic ductal adenocarcinomaendocrine system diseasespancreatic cancerPharmaceutical ScienceImidazo[21-b][134]thiadiazole derivativeAnalytical Chemistryresistancelcsh:QD241-44103 medical and health sciences0302 clinical medicinelcsh:Organic chemistryPancreatic cancerDrug DiscoverymedicinePhysical and Theoretical ChemistryIC50imidazo[21-<i>b</i>][134]thiadiazole derivatives030304 developmental biologyIndole test0303 health sciencesmigration assayMigration AssayChemistryOrganic ChemistryBiological activityindole compoundsmedicine.diseaseIn vitrodigestive system diseasesIndole compoundChemistry (miscellaneous)Cell culture030220 oncology & carcinogenesisCancer researchMolecular Medicine

description

A new series of imidazo[2,1-b][1,3,4]thiadiazole derivatives was efficiently synthesized and screened for their in vitro antiproliferative activity on a panel of pancreatic ductal adenocarcinoma (PDAC) cells, including SUIT-2, Capan-1 and Panc-1. Compounds 9c and 9l, showed relevant in vitro antiproliferative activity on all three pre-clinical models with half maximal inhibitory concentration (IC50) ranging from 5.11 to 10.8 &micro

yearjournalcountryeditionlanguage
2020-01-14
10.3390/molecules25020329https://research.vumc.nl/en/publications/88636a25-c0fe-4d5a-8f45-5b79c613d01e